Zhang Kun, Han Zhaojie, Zhao Hongmei, Liu Siyao, Zeng Fuchun
Department of Thoracic Surgery, Sichuan Provincial People's Hospital, Chengdu, China.
Department of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing, China.
Ann Transl Med. 2021 Oct;9(20):1523. doi: 10.21037/atm-21-4470.
Lung squamous cell carcinoma (LUSC) approximately accounts for a third of lung cancers. However, the role of N6-methyladenosine (m6A) in LUSC remains largely unknown according to previous studies.
In this study, we investigated the mutations, copy number variants (CNVs), expression of 20 m6A RNA methylation regulators, and clinical data from The Cancer Genome Atlas-LUSC (TCGA-LUSC). These data were used for the training cohort of screening potential biomarkers. The prognostic model of m6A RNA methylation regulators was constructed. A receiver operating characteristic (ROC) analysis was undertaken to determine the area under the curves (AUCs) (for 3- and 5-year survival) for the model. Additionally, the accuracy of the two-gene model was confirmed with external data verifications. Combined two-gene model and clinincal information were performed to construct a nomogram to predict patient's prognostic risk assessment.
Fat mass- and obesity-associated protein () and methyltransferase-like 3 () were identified as potential prognostic biomarkers to evaluate benign and malignant tumors and prognosticate. The following prognostic model of m6A RNA methylation regulators was constructed: risk score = 0.162 × - 0.069 × Patients in low-risk group [median overall survival (mOS), 43.4 months] had longer survival than those with high-risk (mOS, 67.3 months) with P=0.0023. The smoking grade and risk score could be independent prognostic factors (P=0.00098 and P=0.0014, respectively). Ultimately, a nomogram was developed to assist clinicians to predict clinical outcomes.
and are potential prognostic biomarkers of LUSC. The two-gene model's use of prognostic risk scores may provide guidance in the selection of therapeutic strategies.
肺鳞状细胞癌（LUSC）约占肺癌的三分之一。然而，根据以往研究，N6-甲基腺苷（m6A）在LUSC中的作用仍 largely 未知。
在本研究中，我们调查了来自癌症基因组图谱-LUSC（TCGA-LUSC）的突变、拷贝数变异（CNV）、20种m6A RNA甲基化调节因子的表达以及临床数据。这些数据用于筛选潜在生物标志物的训练队列。构建了m6A RNA甲基化调节因子的预后模型。进行了受试者工作特征（ROC）分析以确定该模型的曲线下面积（AUC）（用于3年和5年生存率）。此外，通过外部数据验证确认了双基因模型的准确性。结合双基因模型和临床信息构建列线图以预测患者的预后风险评估。
脂肪量和肥胖相关蛋白（）和甲基转移酶样3（）被确定为评估良性和恶性肿瘤及预后的潜在预后生物标志物。构建了以下m6A RNA甲基化调节因子的预后模型：风险评分 = 0.162× - 0.069×低风险组患者[中位总生存期（mOS），43.4个月]的生存期长于高风险组患者（mOS，67.3个月），P = 0.0023。吸烟分级和风险评分可能是独立的预后因素（分别为P = 0.00098和P = 0.0014）。最终，开发了列线图以帮助临床医生预测临床结果。
和是LUSC的潜在预后生物标志物。双基因模型使用预后风险评分可为治疗策略的选择提供指导。 （注：原文中部分英文括号内容缺失具体信息）
